Yen Kristen's Form 4 filing
Soleno Therapeutics IncSLNO · filed Mar 31, 2025
- Accession no.
- 0001415889-25-009297
- Filed
- Mar 31, 2025
- Trade date
- Mar 27, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 13 non-derivative transactions and 3 derivative transactions. Open-market sales total $6.38M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yen KristenCIK 0001643441 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | Common Stock | SSaleDisposed | −1,769 | $65.97F2 | −$116,700.93 | 81,236 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −2,881 | $66.79F4 | −$192,421.99 | 78,355 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −5,239 | $67.70F5 | −$354,680.3 | 73,116 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −6,891 | $68.79F6 | −$474,031.89 | 66,225 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −3,990 | $69.84F7 | −$278,661.6 | 62,235 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −411 | $70.73F8 | −$29,070.03 | 61,824 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −597 | $71.74F9 | −$42,828.78 | 61,227 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −91 | $72.64F10 | −$6,610.24 | 61,136 | Direct | |
| Mar 27, 2025 | Common Stock | MOption exerciseAcquired | +4,888 | $5.10 | +$24,928.8 | 66,024 | Direct | |
| Mar 27, 2025 | Common Stock | MOption exerciseAcquired | +3,750 | $2.41 | +$9,037.5 | 69,774 | Direct | |
| Mar 27, 2025 | Common Stock | MOption exerciseAcquired | +32,000 | $5.25 | +$168,000 | 101,774 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −50,156 | $66.00F11 | −$3,310,296 | 51,618 | Direct | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −23,475 | $66.95F12 | −$1,571,651.25 | 28,143 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | Common Stock | MOption exerciseDisposed | −4,888 | $0.00 | $0 | 2,445 | Direct | |
| Mar 27, 2025 | Common Stock | MOption exerciseDisposed | −3,750 | $0.00 | $0 | 11,667 | Direct | |
| Mar 27, 2025 | Common Stock | MOption exerciseDisposed | −32,000 | $0.00 | $0 | 55,392 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $65.15 to $66.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $66.24 to $67.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $67.24 to $68.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $68.24 to $69.225. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $69.24 to $70.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F8
This transaction was executed in multiple trades at prices ranging from $70.24 to $71.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $71.26 to $72.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $72.31 to $72.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F11
This transaction was executed in multiple trades at prices ranging from $65.74 to $66.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F12
This transaction was executed in multiple trades at prices ranging from $66.75 to $67.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer title: SVP Global Clinical Operations and Patient Advocacy